MOSCOW: In June 2014, Russia launched a unique production of full cycle microsources for the treatment of prostate cancer with low dose brachytherapy. The high-tech complex, total investments in which amounted to 688 million rubles ($8.7 million), was established in Dubna, the international nuclear physics research center and one of the largest scientific foundations in Russia.
“Since 2016, it is planned to export [the microsources] — to the countries of the Eurasian Economic Union and the Middle East,” the Minister of Investments and Innovations Denis Butsaev was quoted in the press release as saying.
Since 2004, some 7,000 surgeries were conducted with the use of the German microsources, the ministry recalled.
Prostate cancer is a malignant tumor, currently one of the most common forms of cancer among Russian men. About 14,000 Russian males are diagnosed with the disease each year and mortality in the first year after diagnosis is over 10 percent. Brachytherapy has become a widely used therapy in many countries during recent years, and has proved effective as well.
